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Abstract Phenethyl isothiocyanate (PEITC) is a naturally
occurring electrophile which depletes intracellular glutathi-
one (GSH) levels and triggers accumulation of reactive
oxygen species (ROS). PEITC is of considerable interest
as a potential chemopreventive/chemotherapeutic agent, and
in this work, we have investigated the effects of PEITC on
human breast cancer cell lines. Whereas PEITC readily
induced apoptosis in MDA-MB-231 cells (associated with
rapid activation of caspases 9 and 3, and decreased expres-
sion of BAX), MCF7 cells were relatively resistant to the
apoptosis promoting effects of PEITC. The relative resis-
tance of MCF7 cells was associated with high basal expres-
sion of NRF2, a transcription factor that coordinates cellular
protective responses to oxidants and electrophiles and raised
intracellular levels of GSH. This raised basal expression of
NRF2 appeared to be a response to on-going production of
ROS, since treatment with the antioxidant and GSH precur-
sor N-acetylcysteine (NAC) reduced NRF2 expression.
Moreover, pre-treatment of MDA-MB-231 cells with NAC
rendered these cells relatively resistant to PEITC-induced
apoptosis. In summary, our data confirm that PEITC may be
an effective chemopreventive/therapeutic agents for breast
cancer. However, differences in the basal expression of
NRF2 and resultant changes in GSH levels may be an
important determinant of sensitivity to PEITC-induced
apoptosis.
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Introduction
Phenethyl isothiocyanate (PEITC) is a naturally occurring
electrophilic compound that readily undergoes thiocarba-
moylation reactions with cellular thiols. Following uptake
into cells, the predominant initial reaction of PEITC is with
glutathione (GSH) the major intracellular antioxidant
(Zhang 2000, 2001). PEITC conjugates are then effluxed
from the cell but breakdown of extracellular PEITC conju-
gates results in liberation of PEITC which is free to re-enter
the cell. The net outcome is a rapid depletion of intracellular
GSH and accumulation of intracellular PEITC. GSH deple-
tion results in increased accumulation of reactive oxygen
species (ROS). The production of intracellular ROS may
also increase due to PEITC-mediated inhibition of mito-
chondrial oxidative phosphorylation (Trachootham et al.
2006; Xiao et al. 2010). Free intracellular PEITC then
reacts with cysteinyl thiols of cellular proteins, potentially
leading to altered protein function (Mi et al. 2007; Xu and
Thornalley 2001).
PEITC has received considerable attention due to its
potential chemopreventive and chemotherapeutic activities
(Cavell et al. 2011; Cheung and Kong 2010; Hayes et al.
2008). PEITC decreases carcinogen-induced cancer devel-
opment in vivo and interferes with the activation of carci-
nogens via inhibition of phase I metabolism and activation
of phase II metabolism. PEITC also exerts direct anti-cancer
effects against established cancer cells in vitro, including
inhibition of cell cycle progression, induction of apoptosis,
decreased migration/invasion and/or suppression of angio-
genesis. Consistent with this, PEITC exerts therapeutic
effects in genetically induced and xenograft tumour models
in vivo. PEITC and other related dietary isothiocyanates are
thought to play an important role in mediating potential anti-
cancer effects associated with diets with a high content of
S. S. Syed Alwi : B. E. Cavell :A. Donlevy :G. Packham (*)
Cancer Research UK Centre, Cancer Sciences Unit, University of
Southampton Faculty of Medicine, Southampton General Hospital,
Somers Cancer Research Building (MP824), Tremona Road,
Southampton SO16 6YD, UK
e-mail: gpackham@soton.ac.uk
Cell Stress and Chaperones (2012) 17:529–538
DOI 10.1007/s12192-012-0329-3
cruciferous vegetables (Kim and Park 2009; Higdon et al.
2007). The chemopreventive/therapeutic effects of PEITC
are currently being explored in clinical studies in low grade
B-cell lymphoma and lung cancer (NCT00968461,
NCT00691132; http://clinicaltrials.gov/).
It is likely that both increased ROS levels and protein
thiocarbamoylation contribute to the biological effects of
PEITC in cancer cells. For example, thiocarbamoylation of
KEAP1 is thought to be important for the induction of the
NRF2 transcription factor, a master regulator of antioxidant/
electrophile responsive genes (Cheung and Kong 2010;
Hayes and McMahon 2009). In normal cells, KEAP1 asso-
ciates with NRF2 and targets it for degradation via the
proteasome. Treatment of cells with isothiocyantes triggers
the release of NRF2 from KEAP1 resulting in stabilisation
of NRF2. Once NRF2 accumulates in the nucleus it acti-
vates a battery of downstream target genes involved in
antioxidant defences, including γ-glutamylcysteine synthe-
tase, the rate-limiting enzyme for the biosynthesis of GSH,
GSH reductase and GSH peroxidase. Thus, pro-oxidant/
electrophilic stress activates a NRF2-dependent feed-back
loop resulting in increased expression oxidant/electrophile
protective proteins.
Breast cancer is the most common malignancy amongst
women in the Western world, responsible for over 450,000
deaths worldwide in 2008 (Ferlay et al. 2008). Breast cancer
can be divided into various molecular subtypes (Perou et al.
2000), and these each have prognostic and therapeutic
implications. A major subset of tumours is characterised
by the expression of oestrogen receptor (ER), and in these
patients, tamoxifen reduces the risk of recurrence of breast
cancer by approximately one half, and reduces the risk of
death from breast cancer by one quarter. A second subset of
tumours express the HER2 receptor, and in these patients,
the anti-HER2 antibody trastuzumab reduces risk of death
from breast cancer by approximately half and the risk of
recurrence by about one third (Smith et al. 2007). In contrast
triple negative breast cancer, characterised by lack of ex-
pression of ER, progesterone receptor, and HER2 constitute
~15% of women (Foulkes et al. 2010), are associated with
adverse prognosis, and currently have no biological thera-
pies available.
Several studies have suggested that PEITC may be an
effective preventive/therapeutic agent in breast cancer.
PEITC has been shown to promote apoptosis in breast
cancer cells (Hahm and Singh 2011; Lee and Cho 2008;
Tseng et al. 2004) and to decrease ER expression (Kang and
Wang 2010). Induction of apoptosis has been associated
with increased expression of the pro-apoptotic BAX and
BIM proteins (Hahm and Singh 2011; Lee and Cho 2008;
Tseng et al. 2004). PEITC can also interfere with pro-
angiogenic pathways via down-modulation of the HIF1α
transcription factor (Wang et al. 2009).
In this work, we have investigated the effects of PEITC
on human breast cancer cell lines. In particular, we have
investigated potential mechanisms that mediate differential
sensitivity of these cells to PEITC. Our work suggests that
differences in basal levels of NRF2 influence the apoptotic
response to PEITC.
Materials and methods
Cell culture and chemicals
MCF7, BT549, MDA-MB-231, ZR-75-1, SKBR3, and
T47D human breast cancer cells were obtained from Amer-
ican Type Culture Collection (Manassas, VA, USA). Cell
lines were maintained in Dulbecco's Modified Eagle's me-
dium (DMEM; Lonza group Ltd, Basel, Switzerland)
supplemented with 10% (v/v) fetal calf serum (PAA Labo-
ratories, Yeovil, UK), 1 mM L-glutamine and penicillin/
streptomycin (Lonza group Ltd). PEITC, indol-3-
carbinol, quercetin, buthionine sulfoximine (BSO), staur-
osporine, and N-acetylcysteine (NAC) were from Sigma
Chemicals (Poole, UK). Dimethylsulfoxide (DMSO) was
used as a solvent control and was added at a dilution
equivalent to the highest concentration of PEITC tested
in each assay.
Growth inhibition
Cells were plated at a density of 20,000 cells per well of a
96-well plate in 50 μl complete growth media. The follow-
ing day cells were treated with PEITC or DMSO as a solvent
control or were left untreated. After 6 days, relative cell
number was determined using the CellTiter 96® AQueous
One Solution Reagent (Promega, Southampton, UK)
according to the manufacturer's instructions. Relative cell
number was calculated as a percentage of untreated cells.
IC50 values were determined by linear regression using
GraphPad Prism (GraphPad Software Inc., La Jolla, CA,
USA).
Apoptosis and cell cycle
To determine the proportion of cells in different phases of
the cell cycle, drug-treated cells were collected by centrifu-
gation and fixed in 70% (v/v) ice cold ethanol and stored at
4°C. On the day of analysis, cells were collected by centri-
fugation and resuspended in 300 μl phosphate buffered
saline containing 100 μg ml−1 RNAse and 8.3 μg ml−1
propidium iodide (Sigma Chemicals) for 15 min. Cell fluo-
rescence was analysed using a FACS Canto (Becton Dick-
inson, Oxford, UK). The proportion of cells in G1, S, or G2/
M phases of the cell cycle was calculated as a proportion of
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all cells in cycle, and the proportion of cells with <G1
content was calculated as a proportion of all cells. Apoptosis
was analysed by annexin V/propidium iodide staining
(Pickering et al. 2007).
Immunoblotting
Immunoblots were performed as previously described
(Brimmell et al. 1999) using equal amounts of protein
lysates (quantified using the BioRad assay) and antibodies
specific for caspase 9, caspase 7, cleaved caspase 9, cleaved
caspase 3, (all Cell Signalling Technology, Beverly, MA,
USA), BAX, BCL2, NRF2 (all Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and a rabbit anti-β-actin antibody
(Sigma Chemicals). Horseradish peroxidase conjugated sec-
ondary antibodies were from GE Healthcare UK (Amer-
sham, UK) and bound immunocomplexes were detected
using SuperSignal West Pico Chemiluminescent reagents
(Perbio Science UK Ltd, Northumberland, UK). Immuno-
blot signals were quantified using Quantity One image
analysis software (BioRad, Hemel Hempstead, UK).
GSH assays
GSH/GSSG assays were performed using kits from Cam-
bridge Bioscience (Cambridge, UK) Company. The concen-
tration of GSH and GSSG were determined by the end-point
method.
Results
PEITC-induced growth inhibition in human breast cancer
cell lines
We first investigated the effects of PEITC on the growth of a
panel of human breast cancer cell lines using the MTS assay.
All cell lines were sensitive to PEITC but there was a ~4-
fold variation in their sensitivity (Table 1). The most sensi-
tive cell line was MDA-MB-231, whereas the least sensitive
was ZR-75-1. Overall, there was no clear correlation be-
tween breast cancer “sub-type” and sensitivity, at least in
this small panel of cell lines. MCF7 and MDA-MB-231
cells were selected for more detailed studies since these
lines are widely used as models in breast cancer research
and showed a significant difference in sensitivity to PEITC
(mean (±SD) IC50 values from up to 9 determinations; 7.2±
1.4 μM and 10.6±1.4 μM for MDA-MB-231 and MCF7
cells, respectively; p00.0003 Student's t test).
We also investigated the response of MDA-MB-231 and
MCF7 cells to other phytochemicals, indol-3-carbinol and
quercetin. Whereas MDA-MB-231 and MCF7 were approx-
imately equally sensitive to indol-3-carbinol (IC50s of 77±
5.1 μM and 89±8.1 μM, respectively), MCF7 cells were
more sensitive to quercetin-mediated growth inhibition
compared to MDA-MB-231 cells (IC50s of 74±8.0 μM
and 111±8.2 μM, respectively). Thus, the relative sensitiv-
ity of MDA-MB-231 cells to PEITC does not reflect a
general increase in sensitivity to growth inhibition.
Effect of PEITC on cell cycle arrest and apoptosis
To investigate in more detail the differential responses of
MDA-MB-231 and MCF7 cells, we first analysed the
effects of PEITC (10 or 20 μM) on cell cycle parameters
at 24 and 48 h after treatment (Fig. 1). In MDA-MB-231
cells, PEITC predominantly induced a G2/M phase arrest
associated with an increased proportion of cells in G2/M
and a reduction of cells in G1 phase. There was also an
increase in the proportion of cells in S phase, and cells with
sub-G1 DNA content, indicative of cell death, especially
after 48 h. PEITC also induced a G2/M phase arrest at 24 h
in MCF7 cells, although to a lesser extent than in MDA-
MB-231 cells, whereas at 48 h, there was a tendency to-
wards a modest increase in the proportion of cells in the G1/
S phases. Overall, there was only a very modest increase in
the proportion of cell with sub-G1 DNA content in PEITC-
treated MCF7 cells.
We also directly investigated the effects of PEITC on
apoptosis (Fig. 2). In MDA-MB-231, PEITC induced rela-
tively high levels of apoptosis, especially at 48 h after
treatment (Fig. 2a). By contrast, in MCF7 cells, PEITC
induced only low levels of apoptosis (Fig. 2b).
Therefore, MCF7 and MDA-MB-231 cells show differ-
ent biological responses to PEITC. PEITC readily induces
apoptosis in MDA-MB-231 cells but not in MCF7 cells.
PEITC induces cell cycle arrest in both lines, although the
specific phase of arrest may be distinct.
Table 1 Summary of results for PEITC-induced growth inhibition
Cell line Status IC50 (μM)
c
ERa PRb HER2
MDA-MB-231 −ve −ve Normal 7.2±1.4
T47D +ve +ve Normal 9.2±3.8
BT549 −ve −ve Normal 11.9±7.3
MCF7 +ve +ve Normal 10.6±1.4
SKBR3 −ve −ve Amplified 26.4±2.1
ZR-75-1 +ve −ve Normal 40.4±4.8
a Estrogen receptor
b Progesterone receptor
c PEITC IC50, mean±SD derived from a minimum of three indepen-
dent experiments
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Fig. 1 Cell cycle analysis in PEITC-treated cells. a, b MDA-MB-231
cells or c, d MCF7 cells were treated with PEITC (10 or 20 μM) or
DMSO as a control for a, c 24 or b, d 48 h. The proportion of cells in
different cell cycle phases was determined using propidium iodide
staining and flow cytometry. Data shown are means±SD derived from
three independent experiments. Statistically significant differences
between DMSO and PEITC treated cells are indicated (*p<0.05;
**p<0.005)
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Fig. 2 Apoptosis analysis in PEITC-treated cells. a, b MDA-MB-231
cells or c, d MCF7 cells were treated with PEITC (10 or 20 μM) or
DMSO as a control for a, c 24 or b, d 48 h. Induction of apoptosis was
analysed using annexin V (An)/propidium iodide (PI) staining (open
bars, An−/PI−; closed bars, An+/PI−; grey bars, An+/PI+; hatched
bars, An−/PI−). Data shown are means±SD derived from three inde-
pendent experiments. Statistically significant differences between
DMSO and PEITC treated cells are indicated (*p<0.05; **p<0.005)
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Effect of PEITC on caspases, BAX, and BCL2
The major difference between MDA-MB-231 and MCF7 in
terms of response to PEITC was their differential sensitivity
to PEITC-induced apoptosis. To confirm this, we investi-
gated the expression of caspases in PEITC treated cells. In
MDA-MB-231 cells, we analysed activation of the initiator
caspases for the intrinsic and extrinsic pathways, caspase 9
and caspase 8, respectively, using antibodies that detected
both the pro-caspase and activated (cleaved) forms of these
caspases. We also analysed activation of the executioner
caspase, caspase 3, using an antibody specific for the acti-
vated form of caspase 3 (Fig. 3). Similar experiments were
performed in MCF7 cells, except we used an antibody that
detected pro-caspase and activated (cleaved) forms of the
executioner caspase, caspase 7, since these cells do not
express caspase 3.
In MDA-MB-231 cells, PEITC treatment resulted in clear
processing of caspase 9 and accumulation of active caspase
3. Caspase activation was detected at 2 h and was further
increased at 4 and 6 h after addition of PEITC. By contrast,
there was no evidence for processing of caspase 8. In MCF7
cells, there was a general decrease in the expression of the
pro-caspase forms of caspases 9, 8 and 7, but no evidence
for accumulation of active forms (Fig. 3b). These results
confirm the differential induction of apoptosis in MDA-MB-
231 and MCF7 cells and indicate that PEITC induces apo-
ptosis via the intrinsic pathway.
We analysed the effects of PEITC on expression of BAX,
a pro-apoptotic BCL2 family protein which has previously
been demonstrated to be increased in PEITC-treated in
human ovarian and breast cancer cell lines (Hahm and Singh
2011; Lee and Cho 2008; Satyan et al. 2006). An increase in
BAX expression was observed at 2 h after addition of
PEITC in MDA-MB-231 cells, and BAX levels further
increased at 4 and 6 h (Fig. 4). By contrast, PEITC treatment
did not alter BAX expression in MCF7 cells. PEITC also
did not alter expression of BCL2 in either cell line.
Effect of PEITC on NRF2
PEITC treatment can elicit increases in intracellular ROS
and one possible explanation for the differential response of
MCF7 and MDA-MB-231 cells was that these cells differed
in their basal levels of ROS or in their ability to tolerate
increased ROS (Trachootham et al. 2006). We therefore
went on to analyse the expression of NRF2 as a surrogate
marker of oxidative stress since NRF2 is induced in cells
with high levels of oxidative or electrophilic stress and plays
a key role in induction of downstream antioxidant defences.
Immunoblot analysis demonstrated that basal (i.e., unin-
duced) levels of NRF2 were 60±17% lower in MDA-MB-
231 cells compared to MCF7 cells (Fig. 5a; mean of 3
determinations, Student's t test p00.025). PEITC increased
NRF2 expression by ~3-fold in MDA-MB-231 cells at 4 h
after treatment with PEITC. By contrast, NRF2 expression
in MCF7 cells was not effected by PEITC (Fig. 5).
Effect of PEITC on total GSH and GSSG
The association between basal NRF2 expression and sensi-
tivity to PEITC suggested that differences in GSH content
might influence responses of MDA-MB-231 and MCF7
cells. We therefore analysed the levels of total GSH and
oxidised GSH (GSSG) in MDA-MB-231 and MCF7 cells,
before and following addition of PEITC (Fig. 6).
In untreated cells, the levels of both total GSH and GSSG
were higher in MCF7 cells, compared to MDA-MB-231
cells. GSH levels were ~50% higher in MCF7 cells. The
ratio of GSSG to total GSH was also higher in MCF7 cells
compared to MDA-MB-231 cells.
Total GSH and GSSG levels were reduced in MCF7 cells
at 2 h after treatment with PEITC, but then remained at this
level for the remainder of the time course. Overall, the GSH/
GSSG ratio was not substantially altered and even after 6 h
treatment the concentration of total GSH was approximately
equivalent to that of untreated MDA-MB-231 cells
(~12 μM). By contrast, in MDA-MB-231 cells, total GSH
levels decreased up to 6 h and were reduced by ~50% at this
time. There was also an increase in the GSSG/GSH ratio,
indicative of increasing oxidative stress.
Effects of NAC on NRF2 expression and PEITC-induced
apoptosis and cell cycle arrest
We next determined whether the relatively high levels of
basal NRF2 expression in MCF7 cells was influenced by
on-going oxidative stress in these cells. MCF7 cells were
pretreated with the antioxidant and GSH precursor NAC, or
left untreated as a control, and then treated with PEITC for
various times. Treatment with NAC alone reduced basal
NRF2 expression in MCF7 cells by ~90% (Fig. 5). Whereas
NRF2 was not induced by PEITC in the absence of NAC,
treatment with PEITC after NAC pre-treatment resulted in a
~4-fold induction in NRF2 expression from this reduced
basal level. In MDA-MB-231 cells, pretreatment with
NAC alone further reduced the already low levels of basal
NRF2 expression in MDA-MB-231 cells and NRF2 was no
longer detectable in these cells. Addition of PEITC to
NAC-pretreated cells did not detectably increase NRF2
expression.
To investigate the role of GSH in determining responses
to PEITC, we analysed the effect of NAC on PEITC-
induced growth inhibition (MTS assay) in MCF7 and
MDA-MB-231 cells. Pre-treatment with NAC increased
the IC50 of MDA-MB-231 cells by ~5-fold (i.e., to 45±
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4.0 μM, Student's t test versus no NAC pre-treatment, p0
0.004). By contrast, the IC50 for PEITC in MCF7 cells was
not significantly affected by NAC pre-treatment (11.4±
4.7 μM versus 18.3±1.4 μM, Student's t test, p00.267).
Pre-treatment with NAC effectively prevented both the
PEITC-induced G2/M arrest and induction of apoptosis in
MDA-MB-231 cells (Fig. 7).
Discussion
PEITC is a potential chemopreventive/chemotherapeutic
agent, and, with other related phytochemicals, is thought
to contribute to the potential protective effects of diets rich
in cruciferous vegetables. It is therefore important to under-
stand the mechanisms by which this electrophilic compound
exerts its anti-cancer effects and what determines differential
responses. Here, we show that individual breast cancer cell
lines differ in response to PEITC and that the basal levels of
NRF2/GSH may be an important determinant of sensitivity
to PEITC-induced apoptosis.
Several previous studies have investigated effects of
PEITC in breast cancer cells, demonstrating that PEITC
induces apoptosis of human and mouse breast cancer cell
lines in vitro (Hahm and Singh 2011; Lee and Cho 2008;
Tseng et al. 2004) and decreases breast cancer growth in
vivo in a mouse model (McCune et al. 2010). PEITC has
also been shown to decrease expression and function of ER
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Fig. 3 Caspase expression in
PEITC-treated cells. MDA-
MB-231 or MCF7 cells were
treated with PEITC (20 μM) for
the indicated times or DMSO
for 6 h as a control. Expression
of caspase 9, caspase 8, caspase
3 (MDA-MB-231 cells) and
caspase 7 (MCF7 cells) was
analysed by immunoblotting.
β-actin was analysed as a load-
ing control. a Representative
immunoblots. The positions of
migration of pro- and cleaved
forms of caspases are indicated.
b Quantitation. Data shown are
means±SD derived from two
independent experiments for
pro-caspase 9, caspase 9, cas-
pase 3 and pro-caspase 8 in
MDA-MB-231 cells (i–iv, re-
spectively) and pro-caspase 9,
pro-caspase 7 and pro-caspase
8 in MCF7 cells (v–vii, respec-
tively). Expression values were
normalized to that of β-actin.
Statistically significant differ-
ences between DMSO and
PEITC treated cells are indicat-
ed (*p<0.05; **p<0.005). Ac-
tive caspase 9 was not detected
in MCF7 cells
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(Kang and Wang 2010). Here, we have extended this work
demonstrating that PEITC, dependent on the cell line tested,
has the potential to induce both cell cycle arrest and apo-
ptosis, associated with activation of the intrinsic cell death
pathway. The key observation from this work is that breast
cancer cells demonstrate a variable response to PEITC, with
overall sensitivity assessed using the MTS assay varying up
to 4-fold between individual cell lines. There was no clear
correlation between PEITC responsiveness and the breast
cancer subtype represented by these lines. However, the
number of cell lines studied was relatively small and further
studies are required to determine whether distinct breast
cancer subtypes are differentially sensitive to PEITC.
Our mechanistic studies focused on MCF7 and MDA-
MB-231 cells as two very well characterised cell line
models. The relative sensitivity of MDA-MB-231 cells did
not reflect a general increased sensitivity of these cells to
phytochemicals, since these lines showed very similar re-
sponse to indol-3-carbinol, and MCF7 cells were more
sensitive to quercetin compared to MDA-MB-231 cells.
The major determinant of differential response appeared to
be sensitivity to PEITC-induced apoptosis. MDA-MB-231
cells were relatively sensitive to PEITC-induced apoptosis,
whereas PEITC did not induce significant levels of apopto-
sis in MCF7 cells. It is important to recognise that the
differential induction of apoptosis in MDA-MB-231 and
MCF7 cells is relative and not absolute. For example,
PEITC has been shown to induce apoptosis in MCF7 cells
in previous studies (Lee and Cho 2008; Hahm and Singh
2011). However, our study has focused on relatively early
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Fig. 4 BCL2 and BAX
expression in PEITC-treated
cells. MDA-MB-231 or MCF7
cells were treated with PEITC
(20 μM) for the indicated times
or DMSO for 6 h as a control.
Expression of BAX and BCL2
was analysed by immunoblot-
ting. β-actin was analysed as a
loading control. a Representa-
tive immunoblots. b Quantita-
tion. (i) BAX MDA-MB-231
cells, (ii) BAX MCF7 cells, (iii)
BCL2 MDA-MB-231 cells, (iv)
BCL2 MCF7 cells. Data shown
are means±SD derived from
three independent experiments.
Expression values were nor-
malized to that of β-actin. Sta-
tistically significant differences
between DMSO and PEITC
treated cells are indicated (*p<
0.05; **p<0.005)
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time points to probe some of the more immediate changes in
PEITC-treated cells. For example, we studied caspase activa-
tion at up to 6 h, whereas other studies which have demon-
strated PEITC-induced caspase activation in MCF7 cells have
studied caspase activation and BCL2 family protein expres-
sion at 24 h (Lee and Cho 2008). PEITC-induced apoptosis in
MDA-MB-231 cells appeared to be mediated via the intrinsic
pathway since it was associated with increased expression of
BAX, and activation of caspase 9, but not caspase 8. In
contrast to apoptosis, PEITC induced cell cycle arrest in both
cell lines, although there were some differences in the specific
phase of arrest between the two lines.
Our work suggests that NRF2 status may influence re-
sponse to PEITC. NRF2 is a transcription factor that is in-
duced by oxidative/electrophilic stress and regulates a set of
100–200 genes encoding proteins involved in cytoprotection,
including many components of the GSH system (Hayes and
McMahon 2009). NRF2 was constitutively expressed at ~2.5-
fold higher levels in MCF7 cells compared to MDA-MB-231
cells in the absence of PEITC. Raised NRF2 expression
appears to be functionally relevant since MCF7 cells also
contained higher GSH levels than MDA-MB-231 cells.
NRF2 expression is regulated at multiple levels, including
transcription, degradation, and phosphorylation (Cheung and
Kong 2010; Hayes andMcMahon 2009), and the mechanisms
that mediate increased NRF2 expression in MCF7 cells may
be complex. Basal NRF2 expression appeared to be depen-
dent on on-going ROS production in both cell lines since
treatment with NAC effectively reduced NRF2 expression.
Elevated ROS may release NRF2 from KEAP1 mediated
negative control, or may cause activation via enhanced phos-
phorylation, perhaps associated with ROS-mediated inhibi-
tion of phosphatase activity. We speculate that MCF7 cells
may be protected from the pro-apoptotic effects of PEITC
relative to MDA-MB-231 cells by enhanced expression of
NRF2 and resultant increases in levels of GSH. Notably,
NRF2 expression was induced in MDA-MB-231 cells follow-
ing treatment with PEITC. However, maximal induction of
NRF2 was relatively delayed compared to activation of
capases in these cells. Thus, it seems likely that although
MDA-MB-231 can mount a NRF2-mediated antioxidant re-
sponse to PEITC, the kinetics are too effectively counter the
rapid induction of apoptosis in these cells, at least at the
concentrations of PEITC tested here.
The mechanisms leading to increased ROS in MCF7
cells are unclear. However, similar differences between
MDA-MB-231 and MCF7 cells in response to pro-
oxidants have been observed in previous studies. For exam-
ple, the pro-oxidant (tert-butyl-2(4,5-dihydrogen-4,4,5,5-
tetramethyl-3-O-1H-imidazole-3-cationic-1-oxyl-2-pyrroli-
dine-1-carboxylic ester) L-NNP induced higher levels of
ROS and apoptosis in MDA-MB-231 cells compared to
MCF7 cells (Zhang et al. 2011) and 2,3,7,8-Tetrachlorodi-
benzo-p-dioxin (TCDD) induces greater levels of GSH de-
pletion and increased ROS in MDA-MB-231 cells
compared to MCF7 cells (Lin et al. 2007). Oncogenic trans-
formation has been shown to elevate intracellular ROS
(Trachootham et al. 2006) or to promote NRF2-dependent
ROS detoxification (DeNicola et al. 2011), possibly depen-
dent on the level of oncogene expression and or cell type.
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Fig. 5 NRF2 expression in
PEITC-treated cells. a NRF2
expression in untreated MDA-
MB-231 or MCF7 cells was
analysed by immunoblotting. b,
cMDA-MB-231 or MCF7 cells
were treated with PEITC
(20 μM) for the indicated times
or DMSO for 6 h as a control.
Expression of NRF2 and β-
actin (loading control) was
analysed by immunoblotting. b
Representative immunoblots. c
Quantitation. (i) MDA-MB-231
cells, (ii) MCF7 cells. Data
shown are means±SD derived
from three independent experi-
ments. Expression values were
normalized to that of β-actin.
Statistically significant differ-
ences between DMSO and
PEITC treated cells in the ab-
sence of NAC are indicated
(*p<0.05). Statistically signifi-
cant differences between NAC
treated and untreated cells are
indicated (#p<0.05)
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Regardless, differences in the underlying oncogenic drives
in MCF7 and MDA-MB-231 cells may account for differ-
ences in ROS production and sensitivity to PEITC.
In summary, our data confirm that PEITC may be an
effective chemopreventive/therapeutic agents for breast can-
cer. However, it will be important to investigate in more
detail the molecules that influence PEITC responses in
individual tumour types. Cells that have adapted to in-
creased transformation-associated ROS production via
upregulation of antioxidant defence may be less sensitive
to PEITC-induced apoptosis.
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